Vantage Investment Advisors’s Eyegate Pharmaceuticals, Inc. Warrants EYEGW Stock Holding History

Vantage Investment Advisors’s Portfolio EYEGW Stock Details EYEGW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,500	Closed	–	–	823
2018 Q2	$0	Hold	2,500	–	–	﹤0.01%	841
2018 Q1	$0	Hold	2,500	–	–	﹤0.01%	882
2017 Q4	$0	Hold	2,500	–	–	﹤0.01%	867
2017 Q3	$0	Hold	2,500	–	–	﹤0.01%	837
2017 Q2	$0	Hold	2,500	–	–	﹤0.01%	812
2017 Q1	$0	Hold	2,500	–	–	﹤0.01%	824
2016 Q4	$1K	Hold	2,500	–	–	﹤0.01%	772
2016 Q3	$1K	Hold	2,500	–	–	﹤0.01%	757
2016 Q2	$0	Hold	2,500	–	–	﹤0.01%	914
2016 Q1	$2K	Hold	2,500	–	–	﹤0.01%	728
2015 Q4	$2K	Hold	2,500	–	–	﹤0.01%	716
2015 Q3	$3K	Buy	+2,500	New	+$3.09K	﹤0.01%	685

Other funds holding EYEGW

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Vantage Investment Advisors's EYEGW Position: Q3 2018 in Review

Vantage Investment Advisors sold out of Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) in Q3 2018, closing a stake of 2,500 shares.

Vantage Investment Advisors first reported a position in EYEGW in Q3 2015 and held it in 12 quarters. The position peaked at $3K in Q3 2015. 3 funds tracked by Wall St. Rank hold EYEGW as of Q3 2018.

Vantage Investment Advisors reported no remaining Eyegate Pharmaceuticals, Inc. Warrants position as of Q3 2018 after selling out during the quarter.
Vantage Investment Advisors sold 2,500 Eyegate Pharmaceuticals, Inc. Warrants shares in Q3 2018.
Vantage Investment Advisors first reported a position in Eyegate Pharmaceuticals, Inc. Warrants in Q3 2015 and held it in 12 quarters.
Vantage Investment Advisors's Eyegate Pharmaceuticals, Inc. Warrants position peaked at $3K in Q3 2015.
3 funds tracked by Wall St. Rank held Eyegate Pharmaceuticals, Inc. Warrants as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.